Skip to main content
. Author manuscript; available in PMC: 2021 Mar 23.
Published in final edited form as: Cell Rep. 2021 Mar 2;34(9):108797. doi: 10.1016/j.celrep.2021.108797

Figure 3. DNA gyrase and Topo IV act in parallel to resolve HO conflicts.

Figure 3.

(A) Survival of cells harboring either a repressed (HO, HM640; CD, HM1794) or constitutively transcribed (HO, HM211; CD, HM1795) lacZ engineered conflict plated on LB or LB supplemented with novobiocin (300 or 350 ng/mL). Bar graphs are quantification (mean and standard deviation) of three independent biological replicates.

(B) Survival after conditional (IPTG-dependent) depletion of either gyrase or Topo IV in cells harboring either a repressed (HO, HM1951/HM1467; CD, HM1949/HM1468) or constitutively transcribed (HO, HM1952/HM1450; CD, HM1950/HM1469) lacZ engineered conflict plated on LB or LB supplemented with IPTG (as indicated; plates shown are representative plates of the highest concentration).

(C) Survival of cells harboring a novobiocin-resistant gyrB allele, a conditional gyrase depletion (IPTG-dependent) system and a constitutively transcribed (HO, HM2420; CD, HM2421) lacZ engineered conflict plated on LB or LB supplemented with novobiocin (7 μg/mL), LB supplemented with IPTG (10 μM), or both novobiocin and IPTG.

“Trx” refers to transcription of the engineered conflict. n.c., no countable colonies.

See also Figure S3.